[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458093":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":24,"responsibleParty":38,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"University Hospital Augsburg","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Maximilian Schmutz, MD","UH Augsburg","PRINCIPAL_INVESTIGATOR",[14,20],{"name":15,"role":16,"phone":17,"phoneExt":18,"email":19},"Sommer Sebastian, MD","CONTACT","+49-821400","161027","sebastian.sommer@uk-augsburg.de",{"name":21,"role":16,"phone":17,"phoneExt":22,"email":23},"Rainer Claus, MD","3715","rainer.claus@uk-augsburg.de",[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":7},"RECRUITING","Augsburg","Bavaria","86156","Germany","DE",{"type":33,"coordinates":34},"Point",[35,36],10.89851,48.37154,{"lat":36,"lon":35},{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100458093","augsburg-longitudinal-plasma-study-for-the-evaluation-of-liquid-biopsy-as-diagnostic-tool-100458093",false,"NCT05245136","Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.","Augsburg Longitudinal Plasma Study (ALPS) to Study Liquid Biopsy (LBx) as a Tool for Diagnostic Support, Assessment of Disease Progression, and Identification of Mutations During Disease Course in Patients With Solid Neoplasms Receiving Palliative Treatment","ALPS","Inclusion Criteria:\n\n* Written informed consent\n* Age ≥ 18 years\n* Histopathologically confirmed metastatic or locally advanced cancer\n* No curative treatment options, except for germ cell tumors\n* Written Agreement to be followed up at Augsburg University Medical Center\n* Signed written informed consent for the Biobank Augsburg (Biobank-A)\n* Willing to undergo treatment according to standard of care\n* Availability or anticipated availability of tumor tissue at time point of inclusion\n* Anticipated life expectancy of at least 3 months at time point of trial inclusion\n\nExclusion Criteria:\n\n* Psychological condition that would preclude informed consent\n* Additional tumor treatment between acquisition of tumor tissue and trial inclusion","ALL","18 Years",{"count":51,"type":52},3000,"ESTIMATED","OBSERVATIONAL","A prospective observational trial of patients with metastatic cancer of various entities which aims at both clarifying the significance of liquid biopsy and establishing a foundation for translational research.",[56,57,58],"Characteristics Disease","Metastatic Cancer","Solid Tumor","2026-07-29",{"date":61,"type":62},"2026-07-30","ACTUAL",{"date":64,"type":62},"2021-03-29",{"date":66,"type":52},"2030-03",{"name":5,"class":6},1]